[go: up one dir, main page]

MX2013007381A - Composiciones farmaceuticas de tenecteplasa. - Google Patents

Composiciones farmaceuticas de tenecteplasa.

Info

Publication number
MX2013007381A
MX2013007381A MX2013007381A MX2013007381A MX2013007381A MX 2013007381 A MX2013007381 A MX 2013007381A MX 2013007381 A MX2013007381 A MX 2013007381A MX 2013007381 A MX2013007381 A MX 2013007381A MX 2013007381 A MX2013007381 A MX 2013007381A
Authority
MX
Mexico
Prior art keywords
tenecteplase
pharmaceutical compositions
compositions
tnk
treatment
Prior art date
Application number
MX2013007381A
Other languages
English (en)
Other versions
MX356199B (es
Inventor
Maheshwari Kumar Mishra
Pritiranjan Bhandari
Sanjay Singh
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46313261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013007381(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of MX2013007381A publication Critical patent/MX2013007381A/es
Publication of MX356199B publication Critical patent/MX356199B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen composiciones farmacéuticas de tenecteplasa que son seguras y efectivas en el tratamiento de accidente cerebrovascular isquémico agudo en comparación con las composiciones conocidas. Las composiciones de la presente invención se conciben en base a una serie de ensayos de prueba en las diferentes cantidades de TNK y el aislamiento de una cantidad específica que es óptimamente adecuada en términos del efecto deseado de TNK en el tratamiento de accidente cerebrovascular isquémico agudo.
MX2013007381A 2010-12-23 2011-12-16 Composiciones farmacéuticas de tenecteplasa. MX356199B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3516MU2010 2010-12-23
PCT/IN2011/000863 WO2012085933A1 (en) 2010-12-23 2011-12-16 Pharmaceutical compositions of tenecteplase

Publications (2)

Publication Number Publication Date
MX2013007381A true MX2013007381A (es) 2013-08-29
MX356199B MX356199B (es) 2018-05-18

Family

ID=46313261

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007381A MX356199B (es) 2010-12-23 2011-12-16 Composiciones farmacéuticas de tenecteplasa.

Country Status (17)

Country Link
US (2) US20130323227A1 (es)
EP (1) EP2654770B1 (es)
JP (1) JP6375112B2 (es)
CN (1) CN103391785A (es)
AU (1) AU2011346515B2 (es)
BR (1) BR112013015914B1 (es)
CO (1) CO6721059A2 (es)
DK (1) DK2654770T3 (es)
EA (1) EA026017B1 (es)
ES (1) ES2687850T3 (es)
LT (1) LT2654770T (es)
MX (1) MX356199B (es)
MY (1) MY171723A (es)
NZ (1) NZ611706A (es)
PL (1) PL2654770T3 (es)
PT (1) PT2654770T (es)
WO (1) WO2012085933A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3209767T (pt) * 2014-10-21 2020-11-09 Gennova Biopharmaceuticals Ltd Um novo processo de purificação para isolamento e produção comercial de tnk-tpa recombinante (tenecteplase)
JP2020520386A (ja) * 2017-05-16 2020-07-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 急性虚血性脳卒中の処置のための方法及び医薬組成物
WO2019229764A1 (en) * 2018-06-01 2019-12-05 Gennova Biopharmaceuticals Limited Process for production of recombinant tnk-tpa by packed-bed perfusion system
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230752A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis von Magnesiumsalzen und Fibrinolytika
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
SG10201501498VA (en) * 2006-08-29 2015-04-29 Genentech Inc Use of tenecteplase for treating acute ischemic stroke
US8916148B2 (en) * 2006-11-07 2014-12-23 Genentech, Inc. Tissue plasminogen activator variant uses
EP2014760A1 (en) * 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process

Also Published As

Publication number Publication date
EA201300746A1 (ru) 2013-11-29
EP2654770B1 (en) 2018-07-11
CO6721059A2 (es) 2013-07-31
US20160310580A1 (en) 2016-10-27
EP2654770A4 (en) 2014-05-21
WO2012085933A1 (en) 2012-06-28
CN103391785A (zh) 2013-11-13
NZ611706A (en) 2015-04-24
MX356199B (es) 2018-05-18
BR112013015914A2 (pt) 2016-10-11
DK2654770T3 (en) 2018-10-29
LT2654770T (lt) 2018-09-10
BR112013015914B1 (pt) 2021-06-08
PT2654770T (pt) 2018-10-19
ES2687850T3 (es) 2018-10-29
JP6375112B2 (ja) 2018-08-15
MY171723A (en) 2019-10-24
PL2654770T3 (pl) 2018-12-31
EP2654770A1 (en) 2013-10-30
US20130323227A1 (en) 2013-12-05
JP2014502608A (ja) 2014-02-03
AU2011346515A1 (en) 2013-07-04
US9943575B2 (en) 2018-04-17
EA026017B1 (ru) 2017-02-28
AU2011346515B2 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
EP2877159B8 (en) Efflux inhibitor compositions and methods of treatment using the same
AU333421S (en) Showerhead
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
SMT201700340T1 (it) Modulatori di enzimi modificanti metile, composizioni e loro utilizzo
UA109123C2 (uk) Пробіотична композиція для застосування в лікуванні запалення кишечнику
IN2014CN04251A (es)
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
IN2014DN09412A (es)
WO2012073047A3 (en) Compositions and methods
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
PH12015501099A1 (en) Synbiotic composition and use thereof
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
MY171723A (en) Pharmaceutical compositions of tenecteplase
ZA201503604B (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
PH12015501147A1 (en) Synbiotic composition and use thereof
UA73592U (ru) Применение экстракта травы герани крупнокорневищной как средства с противовоспалительной и обезболивающей активностью
UA96649C2 (ru) Применение глюкозамина гидрохлорида как средства фригопротекторной действия
AU337239S (en) Tri maintenance shaft base
UA41660U (en) Use of jacton and mexidol as actoprotector
UA102047C2 (uk) ГЕПАТОЗАХИСНА ТА АНТИОКСИДАНТНА АКТИВНІСТЬ ШТАМУ РЕЛІКТОВИХ БАКТЕРІЙ BACILLUS sp. F
AU2010904022A0 (en) Nitriding of Niobium Steel and Product made thereby

Legal Events

Date Code Title Description
FG Grant or registration